Living with narcolepsy can be challenging, especially when excessive daytime sleepiness and cataplexy disrupt daily life. Lumryz (sodium oxybate), a once-nightly extended-release oral suspension, offers new hope for patients. In this blog post, we will explore the early reaction and experience survey data from 49 neurologists from the ZoomRx panel, shedding light on their initial impressions and likelihood of using Lumryz as a treatment option.
“I have prescribed sodium oxybate 2 x night in the past; Lumryx is an extended release.”
Improved Convenience and Compliance:
One of the standout features of Lumryz is its once-nightly dosing regimen, which differentiates it from the previously approved sodium oxybate formulation, Xyrem. In our survey, neurologists expressed positive first impressions regarding the convenience and improved compliance associated with Lumryz. Patients will no longer have to wake up in the middle of the night for a second dose, potentially leading to better treatment adherence.
“It's really a much more effective form of Xyrem because you don't have to wake up to take the second dose, and most of my patients weren't compliant with that anyway.”
"Has the potential to displace Xyrem."
“Reduced sodium, once nightly dosing which is much more patient friendly than Xywav.”
Positive Efficacy and Safety Data:
Neurologists' first impressions were largely influenced by favorable efficacy and safety data obtained from clinical trials. Lumryz demonstrated promising results in effectively managing excessive daytime sleepiness and cataplexy, two key symptoms of narcolepsy. However, concerns about potential side effects and the need for more real-world data were also noted, highlighting the cautious optimism surrounding this new treatment option.
“Proven efficacy of sodium oxybates for narcolepsy with cataplexy and improved nightly dosing schedule of Lumryz.”
“Good results in clinical trials. my concern is about the potential for abuse.”
“It still has considerable safety issues so that's why it's not a 7/7.”
Considerations and Future Outlook:
While Lumryz garnered positive ratings in terms of likelihood of use, some neurologists expressed the need for more real-world data and a better understanding of its safety profile. The sodium content of the medication was also a topic of concern, although it was perceived to be lower than that of Xyrem.
“I will strongly consider prescribing this new therapy once it has been in the marketplace for about three months.”
Lumryz (sodium oxybate) presents a promising once-nightly treatment option for narcolepsy, addressing the challenges faced by patients who experience excessive daytime sleepiness and cataplexy. Neurologists participating in an early reaction and experience survey have shown interest in Lumryz, primarily due to its convenience, improved dosing schedule, and positive efficacy data. However, caution remains regarding safety considerations and the need for further real-world evidence.
As Lumryz makes its way into clinical practice, ongoing research, and real-world data collection will continue to shape our understanding of its effectiveness and safety. It is through collaborations between healthcare professionals, researchers, and pharmaceutical companies that we can ensure the development of innovative treatments that improve the quality of life for individuals living with narcolepsy.
Have you read our Q1’23 manufacturer perception report yet? We asked more than 150 HCPs to rank the top 10 manufacturers across 6 different attributes in 5 different therapeutic areas.
Get your custom access now.